Profound on-treatment viral suppression with peginterferon alfa-2a (40KD) (PEGASYS (R)) plus lamivudine combination therapy limits the development of YMDD mutations, but does not improve sustained response rates over peginterferon alfa-2a (40KD) alone


Germanidis G., Marcellin P., Lau G., Bonino F., Farci P., Hadziyannis S., ...More

55th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 29 October - 02 November 2004, vol.40 identifier

  • Publication Type: Conference Paper / Summary Text
  • Volume: 40
  • City: Massachusetts
  • Country: United States Of America